Par Pharmaceutical Companies, Inc.

ROBBINS GELLER RUDMAN & DOWD LLP FILES CLASS
ACTION SUIT AGAINST PAR PHARMACEUTICAL COMPANIES, INC.

New York – August 15, 2012 – Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http://www.rgrdlaw.com/cases/parpharma/) today announced that a class action has been commenced in the United States District Court for the District of New Jersey on behalf of all persons who held shares of the common stock of Par Pharmaceutical Companies, Inc. (“Par Pharma”) (NYSE:PRX) as of August 2, 2012, against TPG Capital, L.P., Sky Growth Holding Corporation, and Sky Growth Acquisition Corporation (collectively, “TPG”), and Par Pharma and its Board of Directors (the “Board”) for violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “1934 Act”) in connection with the proposed sale of Par Pharma to TPG, pursuant to which Par Pharma shareholders will receive $50.00 in cash for each share of common stock they own.

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Mark S. Reich of Robbins Geller at 631/367-7100, or via email at mreich@rgrdlaw.com.  If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.rgrdlaw.com/cases/parpharma/.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The complaint charges Par Pharma and its Board and TPG with violations of the 1934 Act.  Par Pharma is a U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.

The complaint alleges that defendants failed to disclose material information in a proxy statement filed with the SEC and publicly disseminated in connection with the proposed sale of Par Pharma to TPG.  According to the complaint, the proxy statement was materially false and misleading because it made numerous material omissions about the process leading up to the agreement between Par Pharma and TPG and the work performed by Par Pharma’s financial advisor, J.P. Morgan Securities LLC, which was retained by Par Pharma to evaluate the fairness of TPG’s offer.

Plaintiff seeks injunctive and equitable relief on behalf of all public shareholders of Par Pharma common stock as of August 2, 2012.  Plaintiff is represented by Robbins Geller, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.

Robbins Geller represents U.S. and international institutional investors in contingency-based securities and corporate litigation.  With nearly 200 lawyers across nine offices, the firm represents hundreds of public and multi-employer pension funds with combined assets under management in excess of $1.5 trillion.  The firm has obtained the largest recoveries in history in six of the eight categories of shareholder class action settlements and has been ranked number one in the number of shareholder class action recoveries in MSCI’s Top SCAS 50 every year since 2003.  According to Cornerstone Research, the firm’s recoveries have averaged 35% above the median for all firms over the past seven years (2005-2011). 

Please visit http://www.rgrdlaw.com for more information.

Contact:

            Robbins Geller Rudman & Dowd LLP

            Mark Reich, 631-367-7100

            mreich@rgrdlaw.com

Report Information

If you have information regarding this case that you would like to make available, please contact us about our investigation.